Fagron
Fagron, a leading global player in the pharmaceutical industry, is headquartered in the Netherlands (NL) and operates extensively across Europe, North America, and Latin America. Founded in 1990, the company has established itself as a pioneer in customised medicines, focusing on compounding and innovative pharmaceutical solutions tailored to individual patient needs. Fagron's core offerings include a diverse range of pharmaceutical products and services, such as sterile and non-sterile compounding, as well as advanced drug delivery systems. What sets Fagron apart is its commitment to quality and innovation, ensuring that healthcare professionals have access to tailored therapies that enhance patient outcomes. With a strong market position and a reputation for excellence, Fagron continues to achieve significant milestones in the pharmaceutical sector, reinforcing its status as a trusted partner in personalised medicine.
DitchCarbon Score
How does Fagron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fagron's score of 35 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fagron's reported carbon emissions
In 2023, Fagron NV reported total greenhouse gas emissions of approximately 170,537,000 kg CO2e. This includes 4,218,000 kg CO2e from Scope 1 emissions, 8,526,000 kg CO2e from Scope 2 emissions (market-based), and a significant 157,794,000 kg CO2e from Scope 3 emissions. Over the years, Fagron has demonstrated a commitment to reducing its carbon footprint, achieving a reduction in total emissions from 13,495,000 kg CO2e in 2019 to 11,587,000 kg CO2e in 2022. Fagron has set ambitious targets to further decrease its emissions. The company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the base year. Additionally, it plans to cut Scope 3 emissions by 25% within the same timeframe. Notably, Fagron is also committed to ensuring that 60% of its suppliers, based on emissions from purchased goods and services, will have science-based targets by 2027. These initiatives align with industry standards and reflect Fagron's dedication to addressing climate change and promoting sustainability within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 2,818,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,200,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,477,000 | 000,000 | 000,000,000 | 0,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fagron is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
